The HCV RNA will be measured at baseline and weeks 2, 4, 8, 12, 24, 36 and 48 of therapy as well as during follow-up. Response to therapy is defined by HCV RNA <1000 IU/ml at weeks 4, 8, and 12 of therapy, which will allow continuation of treatment. Telaprevir will be discontinued if HCV RNA is >1000 IU/ml at weeks 4 or 8 of therapy, and pegylated interferon and ribavirin will be discontinued if HCV RNA is still detectable by week 24 of therapy.